The price of domestically developed COVID-19 treatment Azvudine, has been cut to 11.58 yuan ($1.75) per tablet, so as to be included in China's updated medical reimbursement list from March, the National Healthcare Security Administration said on Wednesday.

The listing price of the oral treatment online ranges from 270 to 330 yuan per bottle in different regions, according to public information.

The updated list will take effect from March 1. Currently, all COVID-19 treatments are temporarily covered by the country's medical insurance program.

Huang Xinyu, an official with the administration, said during an interview with China Central Television that the price cut is large, and has met expectations of medical insurance authorities, reflected the sincerity of the drug developer and will benefit patients.